Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SNY
SANOFI
NASDAQ
$44.37
▲ UP 0.02% (0.01)

KEY STATISTICS

Market Cap$106.54 B
52w High$52.68
52w Low$40.89
Dividend Yield5.58%
FrequencyAnnual
P/E9.67
Volume2.01M
Shares Out.2.40B

COMPANY

LEADERSHIP

Belén Garijo López
CHIEF EXECUTIVE
Belén Garijo López

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 1, 2002
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
76,493

PRICE TARGET

Target High$50.00
Target Low$49.00
Target Median$49.50
Target Consensus$49.50

UPCOMING EARNINGS

DateOct 23, 2026
DayFriday
Rev. Est.$15.18B
OCT
23
FRI

SPLIT RECORD

DATETYPERATIO
2013-09-30Forward5:1
2010-11-17Forward10:1

PRICE

$44.37 ▲ UP 0.02% (+$0.01)
OVERLAYS
$44.40$44.70$45.009:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM44.37

About Sanofi

https://www.sanofi.com ↗

Sanofi develops pharmaceuticals, vaccines, and consumer healthcare products globally, including specialty medicines, vaccines, and wellness items. It collaborates with GSK, Stanford, and Prellis Biologics. Founded in 1973, based in Paris.

INDUSTRY

Drug Manufacturers - General

A PRODUCT SANOFI IS KNOWN FOR

Dupixent (dupilumab)
Dupixent (dupilumab)

Dupixent, Sanofi's top-selling biologic, treats inflammatory diseases like atopic dermatitis, asthma, and COPD, and is central to its growth in the immunology market.

COMPETITORS

COMPETITOR
ABBV COMPARE
AMGN COMPARE
LLY COMPARE
NVS COMPARE
PFE COMPARE

Revenue by Geography

MapREGIONQ2-2022Q4-2022Q2-2023Q4-2023
Reportable Geographical Zones$19.79B $23.21B ▲$20.19B ▼$22.88B ▲
North America$7.88B $11.11B ▲$8.26B ▼$10.95B ▲
FRANCE$1.1B $1.19B ▲$1.17B ▼$1.21B ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
49
LISTED HERE
26
RANKED BY POSITION SIZE
PPH
4.05% · 938.6K
AFTY
4.67% · 832.5K
FENI
0.31% · 797.2K
FVL
0.41% · 752.2K
AVDE
0.17% · 717.8K
PID
3.30% · 667.6K
GMOI
2.80% · 434.1K
PB
PBPH
2.15% · 246.3K
2B70.DE
0.68% · 187.6K
BASV
1.86% · 177.8K
BUSA
2.01% · 147.5K
FLV
1.49% · 125.9K
APIE
0.40% · 104.8K
CVGD
1.95% · 62.0K
DBLV
2.32% · 26.6K
SPWO
0.47% · 23.6K
DIVD
2.16% · 11.5K
BIB
0.37% · 8.3K
PVAL
0.00% · 7.3K
LVHB
2.38% · 6.0K
QQQN
1.49% · 5.1K
DFAX
0.00% · 3.7K
GEQ
0.06% · 2.7K
SILX
0.76% · 2.6K
XEML
2.06% · 2.4K
BA
BAD
1.60% · 2.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
6.61%
HOLDERS
1,161
TOP 12 OF 1,161 · RANKED BY POSITION SIZE
Dodge & Cox
68.9M sh · $3.25B
Fisher Asset Management, LLC
12.6M sh · $593.72M
Morgan Stanley
12.5M sh · $602.82M
Blackrock Inc.
10.1M sh · $490.42M
Bank Of America Corp /De/
9.9M sh · $465.98M
Franklin Resources Inc
7.2M sh · $345.22M
Barrow Hanley Mewhinney & Strauss LLC
7.1M sh · $336.39M
Invesco Ltd.
6.8M sh · $290.04M
Jpmorgan Chase & Co
6.6M sh · $285.5M
Price T Rowe Associates Inc /Md/
5.9M sh · $277.23M
Blackrock, Inc.
5.6M sh · $263.32M
Mondrian Investment Partners Ltd
5.5M sh · $235.59M

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity3
Return On Assets4
Debt To Equity2
Price To Earnings1
Price To Book4
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Lisa McClain
Lisa McClain
Sale (Full)
2025-09-11
 John James
John James
Sale (Full)
2024-09-04
 Ro Khanna
Ro Khanna
Purchase
2023-10-13
 Daniel Goldman
Daniel Goldman
Sale
2023-07-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 5
EQUAL WEIGHT 2
BUY 1
8 GRADES IN THE LAST 12 MONTHS
Morgan Stanley EQUAL WEIGHT Exane BNP Paribas NEUTRAL B of A Securities NEUTRAL UBS NEUTRAL Barclays EQUAL WEIGHT Guggenheim NEUTRAL JP Morgan NEUTRAL Deutsche Bank BUY

SECTORS PEERS

PEERPRICE
AMGN$437.08COMPARE
GILD$149.04COMPARE
PFE$28.55COMPARE
VRTX$548.41COMPARE
BMY$66.95COMPARE
CVS$96.81COMPARE
MDT$92.51COMPARE
GSK$50.58COMPARE